Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference


Stevenage, UK 14 November 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 8.40 am GMT in London, UK.

– Ends –

About Achilles Therapeutics
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.

Achilles was founded by lead investor Syncona Ltd and its original shareholders include the CRT Pioneer Fund, UCL Technology Fund, Cancer Research Technology, with the support of UCL Business (UCLB) and the Francis Crick Institute. For further information please visit the Company’s website at:

Further information:

Achilles Therapeutics
Dr Iraj Ali – Chief Executive Officer
+44 (0)1438 906 906

Julia Wilson – Head of Communications
+44 (0)7818 430877

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
Tel: +44 (0) 203 709 5000

US Investor Relations – Solebury Trout
Lee Stern
+1 646-378-2922

AchillesLatest News

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens


Stevenage, UK 29 May 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that...

Read More +

Achilles Therapeutics to present at Jefferies Virtual Healthcare Conference


Stevenage, UK 28 May, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel...

Read More +

Achilles Therapeutics announces formation of Scientific Advisory Board


– World-leading experts in oncology, immunology and R&D will advise the Company as it advances pipeline of pioneering cancer therapies –...

Read More +